Literature DB >> 12568406

Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFbeta receptor independent manner.

Wendy L Parker1, Mary B Goldring, Anie Philip.   

Abstract

Previous work has implicated transforming growth factor beta (TGFbeta) as an essential mediator of cartilage repair and TGFbeta signaling as a requirement for the maintenance of articular cartilage in vivo. However, the mechanisms regulating TGFbeta action in chondrocytes are poorly understood. Endoglin, an accessory receptor of the TGFbeta receptor superfamily, is highly expressed on endothelial cells and has been shown to potently modulate TGFbeta responses. It is not known whether chondrocytes express endoglin or whether it modulates TGFbeta signaling in these cells. In this study, we show that endoglin is expressed on human chondrocytes at levels comparable with endothelial cells and that it forms higher order complexes with the types I and II TGFbeta receptors. More importantly, we show that endoglin forms a heteromeric complex with betaglycan on these cells at endogenous receptor concentrations and ratios. Endoglin complexes with betaglycan in a ligand-independent and -dependent manner as indicated by co-immunoprecipitation in the absence of TGFbeta and after affinity labeling with radiolabeled TGFbeta, respectively. Also, the endoglin-betaglycan association can occur independently of the type II TGFbeta receptor. These findings, taken together with the available evidence that endoglin and betaglycan are potent modulators of TGFbeta signal transduction, imply that the complex formation between endoglin and betaglycan may be of critical significance in the regulation of TGFbeta signaling in chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12568406     DOI: 10.1359/jbmr.2003.18.2.289

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

1.  Leptin receptor JAK2/STAT3 signaling modulates expression of Frizzled receptors in articular chondrocytes.

Authors:  S Ohba; T M Lanigan; B J Roessler
Journal:  Osteoarthritis Cartilage       Date:  2010-09-22       Impact factor: 6.576

2.  Extracellular matrix deposited by synovium-derived stem cells delays replicative senescent chondrocyte dedifferentiation and enhances redifferentiation.

Authors:  Ming Pei; Fan He
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

3.  Endoglin haploinsufficiency is associated with differential regulation of extracellular matrix production during skin fibrosis and cartilage repair in mice.

Authors:  Anas Alzahrani; Yoon Chi; Kenneth W Finnson; Meryem Blati; Bertrand Lussier; Mohit Kapoor; Stephane Roy; Anie Philip
Journal:  J Cell Commun Signal       Date:  2018-02-27       Impact factor: 5.782

4.  Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure.

Authors:  Paola Ximena Coral-Alvarado; Maria Fernanda Garces; Jorge Eduardo Caminos; Antonio Iglesias-Gamarra; José Félix Restrepo; Gerardo Quintana
Journal:  Int J Rheumatol       Date:  2010-08-24

5.  Plasticity of blood- and lymphatic endothelial cells and marker identification.

Authors:  Johannes Keuschnigg; Sirkku Karinen; Kaisa Auvinen; Heikki Irjala; John-Patrick Mpindi; Olli Kallioniemi; Sampsa Hautaniemi; Sirpa Jalkanen; Marko Salmi
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

6.  Bioreactor-Controlled Physoxia Regulates TGF-β Signaling to Alter Extracellular Matrix Synthesis by Human Chondrocytes.

Authors:  Holger Jahr; Seval Gunes; Annika-Ricarda Kuhn; Sven Nebelung; Thomas Pufe
Journal:  Int J Mol Sci       Date:  2019-04-06       Impact factor: 5.923

Review 7.  Dynamics of Transforming Growth Factor Beta Signaling in Wound Healing and Scarring.

Authors:  Kenneth W Finnson; Sarah McLean; Gianni M Di Guglielmo; Anie Philip
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-06       Impact factor: 4.730

Review 8.  Endoglin in the Spotlight to Treat Cancer.

Authors:  Teresa González Muñoz; Ana Teresa Amaral; Pilar Puerto-Camacho; Héctor Peinado; Enrique de Álava
Journal:  Int J Mol Sci       Date:  2021-03-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.